WhatsApp
backNews Article

Biocon Gets U.S. FDA Approval for Pebrilzo™, a Biosimilar to Perjeta® for HER2-Positive Breast Cancer

Approval marks Biocon’s fifth oncology biosimilar in the U.S. with commercial launch planned for Q3 2028 under a global settlement with Genentech

Biocon Limited announced the U.S. FDA approval of Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta®, to treat HER2-positive breast cancer. This approval expands Biocon’s oncology biosimilar portfolio to five treatments in the U.S. The company also reached a global settlement with Genentech, setting a licensed launch in the U.S. by Q3 2028.

3 days ago|BIOCON-0.44%
Biocon Limited532523BIOCONNew Ventures

Biocon Limited

New Ventures

Biocon Limited announced that the U.S. Food and Drug Administration has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta®, for the treatment of HER2-positive breast cancer, strengthening Biocon's oncology biosimilar offerings in the United States.

Pebrilzo™ is a monoclonal antibody treatment targeting HER2-positive breast cancer by blocking HER2 receptors on cancer cells. It is indicated for metastatic breast cancer in combination with trastuzumab and docetaxel, and for early breast cancer as part of combination therapy.

This approval follows a positive opinion from the European Medicines Agency recommending marketing authorization of Pebrilzo® in Europe for HER2-positive breast cancer across multiple stages.

Biocon has secured a global settlement and license agreement with Genentech enabling the earliest licensed launch of Pebrilzo™ in the U.S. in the third quarter of calendar year 2028.

Biocon’s oncology biosimilar portfolio in the U.S. now includes five approved therapies: Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb), Aukelso® (denosumab-kyqq), and the newly approved Pebrilzo™.

HER2-positive breast cancer is an aggressive breast cancer subtype caused by overexpression of the HER2 protein. About 20% of the approximately 320,000 expected new breast cancer diagnoses in the U.S. in 2026 will be HER2-positive cases.

Highlights

  • FDA approval of Pebrilzo™ for HER2-positive breast cancer treatment
  • Pebrilzo™ is a biosimilar to Perjeta® (pertuzumab) monoclonal antibody
  • Biocon's oncology biosimilar portfolio includes five approved products in the U.S.
  • Global settlement with Genentech enables U.S. commercial launch by Q3 2028
  • EMA recommended marketing authorization for Pebrilzo® in Europe
  • Indications include metastatic and early HER2-positive breast cancer treatment

Key Data Snapshot

FDA Approval DateNovember 16, 2026
Licensed U.S. Commercial Launch DateQ3 calendar year 2028
Number of Biocon Oncology Biosimilars Approved in U.S.Five
Breast Cancer Diagnoses Expected in U.S. in 2026Approximately 320,000 women
Percentage of HER2-Positive Breast Cancer CasesAbout 20%
Company TickersBSE: 532523, NSE: BIOCON

What happened

  • Biocon announced the FDA approval of Pebrilzo™, a biosimilar to Perjeta®, for treatment of HER2-positive breast cancer.
  • Pebrilzo™ is a monoclonal antibody that blocks HER2 receptors, indicated for metastatic and early breast cancer treatment.
  • The approval expands Biocon's oncology biosimilar portfolio in the U.S. to five approved treatments.

Key details

  • Pebrilzo™ will be used in combination with trastuzumab and docetaxel for metastatic breast cancer patients without prior anti-HER2 or chemotherapy for metastatic disease.
  • For early breast cancer, Pebrilzo™ is indicated as part of neoadjuvant and adjuvant treatment regimens.
  • Biocon entered a global settlement with Genentech securing the earliest licensed U.S. launch date of Q3 2028.

Background and context

  • Approximately 320,000 women are expected to be diagnosed with breast cancer in the U.S. in 2026; 20% of these cases are HER2-positive.
  • HER2-positive breast cancer is characterized by overexpression of HER2 protein driving aggressive tumor growth.
  • Biocon’s oncology pipeline includes biosimilars for trastuzumab/hyaluronidase, nivolumab, and pembrolizumab.

Regulatory and governance context

  • FDA approval based on analytical similarity, clinical pharmacokinetic data, quality, safety, immunogenicity, and efficacy of Pebrilzo™ compared to reference biologic Perjeta®.
  • European Medicines Agency’s Committee for Medicinal Products gave a positive opinion recommending marketing authorization for Pebrilzo® in Europe.
  • FDA warnings include potential left ventricular dysfunction and embryo-fetal toxicity associated with pertuzumab treatment.

More News on New Ventures

View all

Latest corporate announcements and market updates in New Ventures.

View all news
Biocon Gets U.S. FDA Approval for Pebrilzo™, a | Stockk News